4//SEC Filing
Cislini Jeff 4
Accession 0001610717-25-000240
CIK 0001628171other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 4:06 PM ET
Size
5.4 KB
Accession
0001610717-25-000240
Insider Transaction Report
Form 4
Cislini Jeff
General Counsel
Transactions
- Sale
Common Stock
2025-06-16$39.83/sh−1,878$74,801→ 56,005 total
Footnotes (4)
- [F1]Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
- [F2]This transaction was executed in multiple trades in prices ranging from $39.5915 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
- [F4]Includes 49,054 RSUs.
Documents
Issuer
Revolution Medicines, Inc.
CIK 0001628171
Entity typeother
Related Parties
1- filerCIK 0001969082
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 4:06 PM ET
- Size
- 5.4 KB